HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment

Occasional cases of viral escape in cerebrospinal fluid (CSF) despite suppression of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We investigated CSF viral escape in subjects treated with commonly used antiretroviral therapy regimens in relation to intrathecal immune ac...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases Vol. 202; no. 12; p. 1819
Main Authors: Edén, Arvid, Fuchs, Dietmar, Hagberg, Lars, Nilsson, Staffan, Spudich, Serena, Svennerholm, Bo, Price, Richard W, Gisslén, Magnus
Format: Journal Article
Language:English
Published: United States 15.12.2010
Subjects:
Adult
Aged
Anti-HIV Agents - pharmacokinetics
Anti-HIV Agents - therapeutic use
Blood-Brain Barrier
Cerebrospinal Fluid - virology
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Female
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - isolation & purification
Humans
Male
Middle Aged
Neopterin - analysis
Plasma - virology
Reverse Transcriptase Polymerase Chain Reaction
RNA, Viral - isolation & purification
Treatment Outcome
Viral Load
ISSN:1537-6613, 1537-6613
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Occasional cases of viral escape in cerebrospinal fluid (CSF) despite suppression of plasma human immunodeficiency virus type 1 (HIV-1) RNA have been reported. We investigated CSF viral escape in subjects treated with commonly used antiretroviral therapy regimens in relation to intrathecal immune activation and central nervous system penetration effectiveness (CPE) rank. Sixty-nine neurologically asymptomatic subjects treated with antiretroviral therapy >6 months and plasma HIV-1 RNA <50 copies/mL were cross-sectionally included in the analysis. Antiretroviral therapy regimens included efavirenz, lopinavir/ritonavir or atazanavir/ritonavir combined with tenofovir, abacavir, or zidovudine and emtricitabine or lamivudine. HIV-1 RNA was analyzed with real-time polymerase chain reaction assays. Neopterin was analyzed by enzyme-linked immunosorbent assay. Seven (10%) of the 69 subjects had detectable CSF HIV-1 RNA, in median 121 copies/mL (interquartile range, 54-213 copies/mL). Subjects with detectable CSF virus had significantly higher CSF neopterin and longer duration of treatment. Previous treatment interruptions were more common in subjects with CSF escape. Central nervous system penetration effectiveness rank was not a significant predictor of detectable CSF virus or CSF neopterin levels. Viral escape in CSF is more common than previously reported, suggesting that low-grade central nervous system infection may continue in treated patients. Although these findings need extension in longitudinal studies, they suggest the utility of monitoring CSF responses, as new treatment combinations and strategies modify clinical practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1537-6613
1537-6613
DOI:10.1086/657342